Wayne State University

Publications and abstracts

Publications

  1. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infectiouns caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial.  Surgical Infections 2003; 4(1):57-70.
  2. Lodise TP, McKinnon PS, Swiderski LM, Rybak MJ. Outcomes Analysis of Delayed Antibiotic Treatment for Hospital-Acquired Staphylococcus aureaus Bacteremia.  Clinical Infectious Diseases 2003; 36(11):
  3. Coyle EA, Cha R, Rybak MJ.  Influence of Linezolid, Penicillin, and Clindamycin, Alone and in Combination, on streptococcal pyrogenic exotoxin A (SPE A) Release.A. Antimicrob Agents Chemother 2003; 47(5): 1752-1755.
  4. Cha R, Grucz RG, Rybak MJ. Daptomycin Dose-Effect Relationship (DAP) Against Resistant Gram-Positive Organisms. Antimicrob Agents Chemother 2003; 47(5): 1598-1603
  5. Kerns RJ, Rybak MJ, Kaatz GW, Vaka F, Cha R, Grucz RG, Diwadkar VU, Ward TD. Piperazinyl-Linked Fluoroquinolone Dimers Possessing Potent Antibacterial Activity Against Drug-Resistant Strains of Staphylococcus aureus.  Bioorganic & Medicinal Chemistry Letters 2003; 13:1745-1749.
  6. White RL, Bonapace CR, Friedrich LV, Rybak MJ, Mercier RC, Houlihan HH, Aeschlimann JR, Bosso JA.  Differences in Antimicrobial Effect Determined with 3 In Vitro Pharmacodynamic Models. Pharmacotherapy 2003(5):603-608.
  7. Cha R, Rybak MJ.  Linezolid and Vancomycin, Alone and in Combination with Rifampin, Compared with Moxifloxacin Against a Multidrug-Resistant and Vancomycin-Tolerant Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model. Antimicrob Agents Chemother 2003; 47(6):1984-1987.
  8. Tam VH, McKinnon PS, Akins RL, Drusano GL, Rybak MJ.  Pharmacokinetics and Pharmacodynamics of Cefepime in Patients with Various Degrees of Renal Function. Antimicro Agents Chemother 2003; 47(6):1853-1861.
  9. Allen GP, Kaatz GW, Rybak MJ. Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model.  Antimicrob Agents Chemother 2003; 47(8):2606-2614.
  10. Lodise Thomas P. Jr., McKinnon Peggy S., Rybak MJ.  Prediction Model to Identify Patients with Staphylococcus aureus Bacteremia at Risk for Methicillin Resistance.  Infection Control and Hospital Epidemiology 2003;  24(9):655-661.
  11. Cha R, Brown WJ, Rybak MJ.  Bactericidal Activities of Daptomycin, Quinupristin-Dalfoprisitin, and Linezolid against Vancomycin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations.  Antimicrobial Agents and Chemotherapy 2003; 47(12):3960-3963.
  12. Cha R, Rybak MJ.   Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.  Diagnostic Microbiology and Infectious Disease; 47 (2003) 539-546.
  13. Tedesco K, Rybak MJ.  Daptomycin: A Review.  Pharmacotherapy; 24(1):41-57.
  14. Allen GP, Kaatz GW, Rybak MJ. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.  In: International Journal of Antimicrobial Agents.
  15. Cha R, Rybak MJ.  Influence of Protein Binding under Controlled Conditions on the Bactericidal Activity of Daptomycin in an In Vitro Pharmacodynamic Model. In: Journal of Antimicrobial Chemotherapy. 2004;54:259-266.
  16. Cha R, Akins RL, Rybak MJ.  Linezolid, levofloxacin, and vancomycin against vancomycin-tolerant and fluoroquinolone-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.  Pharmacotherapy. 2003 Dec;23(12):1531-7
  17. Huang V, Brown WJ, Rybak MJ. In Vitro Activities of a Novel Cephalosporin, CB-181963 (CAB-175), against Methicillin-Susceptible and –Resistant Staphylococcus aureus (MRSA) and Glycopeptide-Intermediate Susceptible Staphulococci Species (GISS).  In: Antimicrobial Agents Chemother. 2004. 48(7):2719-2723.
  18. Allen GP, Kaatz GW, Rybak MJ.  Activities of Mutant Prevention Concentration-targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model. In: Antimicrobial Agents Chemotherapy. 2003;47(8):2606-14.
  19. Rybak MJ. Increased Bacterial Resistance: PROTEKT US – An Update. The Annals of Pharmacotherapy Supplement. 2004 Sep; 38(9): S8-S13.
  20. Cha R, Rybak MJ. Pulsatile delivery of amoxicillin against Streptococcus pneumoniae. In: Journal of Antimicrobial Agents Chemotherapy. 2004;54(6):1067-71.
  21. Allen GP, Kaatz GW, Rybak MJ. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. In: Int Journ of Antimicrob Agents 24(2004):150-160.
  22. Finberg RW, Moellering RC, Tally FP, Craig WA, Pankey GA, Dellinger EP, West MA, Joshi M, Linden PK, Rolston KV, Rotschafer JC, & Rybak MJ. The Importance of Bactericidal Drugs: Future Directions in Infectious Disease. In: Clin Infect Dis. 2004 Nov; 39:1314-20.
  23. LaPlante KL, Rybak MJ. Clinical glycopeptide-intermediate staphylococci tested agaist arbekacin, daptomycin, and tigecycline. In: Diag Micro & Infect Dis. 50(2004)125-130.
  24. LaPlante KL, Rybak MJ.  Daptomycin – a novel antibiotic against Gram-positive pathogens.  In: Expert Opin. Pharmacother. (2004)5(11):2321-2331.
  25. Finberg RW, Moellering RC, Tally FP, Craig WA, Pankey GA, Dellinger EP, West MA, Joshi M, Linden PK, Rolston KV, Rotschafer JC, Rybak MJ. The Importance of Bactericidal Drugs: Future Direction in Infectious Disease. In: Clin Infect Dis. 2004;39:1314-20.
  26. Rybak MJ. Resistance to Antimicrobial Agents: An Update.  In: Pharmacotherapy. 2004;24:203S-215S.
  27. Rybak MJ, LaPlante KL.  Community-Associated Methicillin-Resistant Staphylococcus aureus: A Review. In: Reviews of Therapeutics. Pharmacotherapy 2005;25(1):74-85.
  28. Huang V, Rybak MJ.  Pharmacodynamics of Cefepime Alone and in Combination with Various Antimicrobials against Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Infection Model. In: Antimicrobial Agents and Chemotherapy. 2005;49(1):302-308.
  29. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an invitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2005;2735-2745.
  30. Rybak MJ, Cha R, Cheung CM, Meka VG, Kaatz GW. Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. Diag Microbiol Infect Dis. 2005;51:119-125.
  31. Brown SD,Rybak MJ. Antimicrobial Susceptibility Among Respiratory Tract Pathogens From the Northern States of the USA. Infect Dis Clin Pract 2005; 13: 179-186

ABSTRACTS

  1. Huang V, Rybak MJ. In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-resistant Staphylococcus aureus. 13th European Congress of Clinical Microbiology and Infectious Diseases. Glasgow, Scotland, 5/10-13/03.
  2. Tedesco KL, Rybak MJ. Daptomycin, Linezolid and Vancomycin, against Methicillin Resistant S aureus (MRSA) in an In vitro Pharmacodynamic Model with Simulated Endocardial Vegetations. 6th Annual Conference of Infectious Diseases Pharmacotherapy: Making a Difference 2003. Orlando, FL, 5/03.
  3. Tedesco KL, Rybak MJ. Daptomycin, Linezolid and Vancomycin, against Methicillin Resistant S. aureus in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations.  International Symposium on Modern Concepts in Infective Endocarditis and Cardiovascular Infections.  Chamonix, France.  6/26-28/03.  Abstract 69.
  4. Huang V, Brown WJ, Rybak MJ.  Activities of a Novel Cephalosporin, CB-181963 (CAB-175), againstGlycopeptide-Intermediate Susceptible S. aureus (GISA). 43rd Annual ICAAC. Chicago, IL, 9/14-17/03. Abstract 3621.
  5. Tedesco KL, Rybak MJ.  Impact of High Inoculum S. aureus on the Activities of Nafcillin, Vancomycin, Linezolid, Gentamicin & Daptomycin in an In Vitro Pharmacodynamic Model.  43rd Annual ICAAC.  Chicago, IL.  9/14-17/03.  Abstract 3551.
  6. Doern GV, Rybak MJ.  Activity of Telithromycin against Streptococcus pneumoniae Resistant to Penicillin, Macrolides and Fluoroquinolones Isolated from Respiratory Tract Infections: PROTEKT US Year 2 (2001-2002). 43rd ICAAC.  Chicago, IL. 9/14-17/03.  Abstract 2365.
  7. Rybak MJ, Cheung C, Brown WJ.  In vitro evaluation of CB-181963, Daptomycin, Arbekacin, Tigecycline, Quinupristin/Dalfopristin, Linezolid, Gentamicin, Doxycycline and Rifampin alone and in combination against MRSA, GISA, VRSA and VRE. 43rd ICAAC.  Chicao, IL. 9/13-9/17/03
  8. Tedesco KL, Huang V, Rybak MJ.  In Vitro Activities of Daptomycin, Arbekacin, and Tigecycline (GAR-936) against Several Clinical Glycopeptide-Intermediate S. aureus (GISA) Pathogens.  41st Annual IDSA. San Diego, CA. 10/9-12/03. Abstract 1061.
  9. McKinnon PS, Rybak MJ.  Evaluation of Potential Treatment Options for Community-Onset S. aureus Infections. 41st Annual IDSA. San Diego, CA. 10/9-12/03.  Abstract 335.
  10. Domagala BM, Rybak MJ, McKinnon PS.  Evaluation of a Five-Year Expreience Using a Vancomycin Dosing Nomogram Without Routine Vancomycin Serum Concentration Monitoring. 2003 Midyear Clinical Meeting. New Orleans, LA. 12/7-11/03. Abstract RP-260.
  11. Huang V, Brown M, Rybak MJ.  Evaluation of tigecycline, linezolid, quinupristin-dalfopristin, arbekacin and daptomycin alone and in combination with vaious antimicrobials against two clinical strains of vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model.  2004 ECCMID. Prague, Czech Republic.  5/3/04.  Abstract 1040.
  12. Huang V, Rybak MJ.  Evaluation of cefepime, arbekacin, daptomycin, gentamicin, tobramycin, and tigecycline alone and in combination against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.  2004 ECCMID. Prague, Czech Republic. 5/3/04.  Abstract 1041.
  13. Tedesco K, Rybak MJ. Simultaneous methicillin-resistant Staphylococcus aureus & vancomycin-resistant Enterococcus faecalis infections in an in vitro pharmacodynamic model: a comparison of daptomycin, arbekacin, linezolid, and tigecycline activities. 2004 ECCMID. Prague, Czech Republic.  5/3/04.  Abstract 104.
  14. Farrell D, Rybak MJ, Patel M. Prevalence of β-Lactamase Production among Haemophilus influenzae Isolates Collected in the US Over a 3-Year Period (2000-2003) and the In Vitro Activity of Telithromycin. 2004 Interscience Conference on Antimicrobial Agents and Chemotherapy.  Washington, DC.  10/10-11/2/04.  Abstract C2-807.
  15. Leuthner KD, Cheung C, Rybak MJ. In Vitro Evaluation of Pulsatile Delivery of Clarithromycin Alone and in Combination with Amoxacillin against Streptococcus pneumoniae (SPN) with Reduced Susceptibility to These Agents.  2004 Interscience Conference on Antimicrobial Agents and Chemotherapy.  Washington, DC.  10/10-11/2/04.  Abstract A-1169.
  16. Tsuji BT, Rybak MJ. Evaluation of Daptomycin (D) or Vancomycin (V) in Combination with Traditional or High Dose Short Exposure Gentamicin (G) against S. aureus in an In Vitro Pharmacodynamic Model (IVPM) with Simulated Endocardial Vegetations (SEV).  2004 Interscience Conference on Antimicrobial Agents and Chemotherapy.  Washington, DC.  10/10-11/2/04.  Abstract A-1171.
  17. Tedesco KL, Rybak MJ. Activity of Clindamycin Inducible Resistant Community-Associated Methicillin Staphylococcus aureus (CA-MRSA) versus Daptomycin, Clindamycin, Doxycycline, Linezolid, and Trimethoprim/Sulfamethoxazole in an In Vitro Model.  2004 Interscience Conference on Antimicrobial Agents and Chemotherapy.  Washington, DC.  10/10-11/2/04.  Abstract A-1301.
  18. Tedesco KL, Rybak MJ, Amjad M, Deryke A, Farrell DJ.  Evaluation of Inducible MLSB Resistance and SCCmec Type in Staphylococcus aureus: a Comparison of Community versus Hospital Associated Strains.  2004 Interscience Conference on Antimicrobial Agents and Chemotherapy.  Washington, DC.  10/10-11/2/04.  Abstract C2-1997.
  19. Rybak MJ, Tedesco KL, Amjad M, Mobarak R, Kaatz GW.  Identification of Community-Associated Methicillin Resistant Staphylococcus aureus (CAMRSA) by Clinical and Molecular Methods in a Large Urban Medical Center in Detroit, MI.  2004 Interscience Conference on Antimicrobial Agents and Chemotherapy.  Washington, DC.  10/10-11/2/04.  Abstract C2-2006.
  20. Leuthner KD, Cheung C, Rybak MJ.  Comparison of Telavancin versus Daptomycin, Linezolid and Quinupristin/Dalfopristin against 49 Glycopeptide Non-Susceptible Staphylococcus Species (GISS) Including Hetero-Resistant (hGISS) and Vancomycin Resistant S. aureus (VRSA).  2004 Interscience Conference on Antimicrobial Agents and Chemotherapy.  Washington, DC.  10/10-11/2/04.  Abstract E-2007.
  21. Huang V, Rybak MJ. Evaluation of Tigecycline (TG), Minocycline (MN), Tetracycline (TT), Teicoplanin (TP), and Vancomycin (VN) against Community-Associated (CA-MRSA) and Multidrug-Resistant (MDR-MRSA) Methicillin-Resistant Staphylococcus aureus.  2004 Interscience Conference on Antimicrobial Agents and Chemotherapy.  Washington, DC.  10/10-11/2/04.  Abstract E-2063.
  22. Tsuji BT, Rybak MJ.  Etest and Time Kill Synergy Testing of Clinical Strains of Heteroresistant (h) Glycopeptide-Intermediate S. aureus (GISA) and GISA.  2004 Interscience Conference on Antimicrobial Agents and Chemotherapy.  Washington, DC.  10/10-11/2/04.  Abstract E-2029.
  23. Tsuji BT, Rybak MJ.  The influence of Staphylococcus aureus accessory gene regulator function on the development of glycopeptide heteroresistance in an in vitro pharmacodynamic model.  15th Annual European Congress of Clinical Microbiology and Infectious Diseases. 04/04/05.
  24. Tsuji BT, Rybak MJ, Cheung C, Amjad M.  Bactercidal activity of daptomycin, tigecycline, teicoplanin and vancomycin against community-associated and multidrug-resistant methicillin-resistant Staphylococcus aureus.  15th Annual European Congress of Clinical Microbiology and Infectious Diseases. 04/04/05.
  25. LaPlante K, Rybak MJ, Tsuji B, Kaatz G.  Resistance in Streptococcus pneumoniae: AUC/MIC breakpoints differ between gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.  15th Annual European Congress of Clinical Microbiology and Infectious Diseases. 04/04/05.
  26. Davis S, Rybak MJ, Domagala B, McKinnon P.  Predicted AUC/MIC using simple vancomycin nomogram exceeds proposed pharmacodynamic targets for Staphylococcus aureus infections.  15th Annual European Congress of Clinical Microbiology and Infectious Diseases. 04/04/05.
  27. Leuthner KL, Rybak MJ, Sader HS, Jones RN.  Comparison of in vitro activity of cefepime alone or in combination with sulbactam against clinical strains of multi-drug resistant Acinetobacter spp.  15th Annual European Congress of Clinical Microbiology and Infectious Diseases. 04/04/05.